We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BBY:NYSEBest Buy Co., Inc. Analysis

Data as of 2026-05-25 - not real-time

$61.63

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

BBY is trading below its long‑term moving average, indicating a bearish backdrop despite recent price strength. The stock sits above the short‑term SMA but remains under the mid‑term SMA, suggesting limited upward momentum. RSI is in the mid‑50s, reflecting neutral momentum without clear overbought pressure. MACD histogram is positive and the signal line has turned bullish, providing a technical hint of a possible short‑term rebound. Volume has been rising, supporting the recent price gains. The broader market sentiment is in an “Extreme Greed” phase, which could add speculative pressure to the stock.
Fundamentals show a modest PE multiple and a high dividend yield, positioning BBY as a value‑oriented play. However, the DCF fair‑value estimate sits well below the current market price, pointing to an overvaluation gap. The company’s revenue is essentially flat and operating margins are thin, limiting growth upside. Debt levels are elevated relative to equity, which raises balance‑sheet risk despite solid free cash flow. The sector’s cyclical nature and current economic uncertainty add medium‑level sector risk. Overall, the stock offers a high dividend but limited upside, warranting a cautious stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price above short‑term SMA but below mid‑term SMA
  • neutral RSI and bullish MACD signal
  • rising volume amid bearish trend

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • high dividend yield with sustainable payout
  • moderate PE offering value appeal
  • potential modest upside despite overvaluation

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • flat revenue growth limiting long‑term expansion
  • elevated debt relative to equity
  • steady free cash flow supporting dividend continuity

Key Metrics & Analysis

Financial Health

Revenue Growth-1.00%
Profit Margin2.56%
P/E Ratio12.2
ROE37.04%
ROA7.52%
Debt/Equity139.47
P/B Ratio4.3
Op. Cash Flow$2.0B
Free Cash Flow$842.5M

Technical Analysis

TrendBearish
RSI56.3
Support$55.10
Resistance$62.33
MA 20$58.67
MA 50$61.52
MA 200$69.75
MACDBullish
VolumeIncreasing
Fear & Greed Index91.77

Valuation

Fair Value$41.39
Target Price$71.55
Upside/Downside16.10%
GradeOvervalued
TypeValue
Dividend Yield6.23%

Risk Assessment

Beta0.99
Volatility35.50%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.